Skip to main content

Verisante Raises $310,000 in Private Placement

Premium

Verisante Technology said it has raised C$350,000 ($310,000) in a non-brokered private placement.

The placement, from unidentified Chinese investors, consisted of 2.5 million common shares at a price of C$.14 per share.

With this placement, the Chinese group has now invested C$650,000 of the C$2.15 million they have agreed to put into Verisante over the next 24 months as per an agreement between the two parties.

The money will be used for working capital requirements, Verisante said.

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.